Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1998-09-10
2004-04-06
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S192100, C424S234100, C424S184100, C530S300000, C530S328000, C530S350000, C530S825000, C514S002600, C435S069700, C435S069300
Reexamination Certificate
active
06716433
ABSTRACT:
TECHNICAL FIELD
The present invention provides pharmaceutical compositions and methods, and in particular, vaccines for use in preventing Group A streptococcal infections.
BACKGROUND OF THE INVENTION
Streptococci are a group of bacteria with the capacity to grow in chains. Many varieties are part of the normal bacterial flora in humans and are not especially harmful. However, a particular group of streptococcal bacteria, called group A and represented by
Streptococcus pyogenes,
is a human pathogen. Briefly, group A streptococci cause a variety of human illnesses, ranging from uncomplicated pharyngitis and pyoderm a to life-threatening infections associated with toxic shock syndrome, deep tissue invasion and sepsis. In some individuals, untreated streptococcal pharyngitis may be followed by acute rheumatic fever. In recent years there has been a dramatic increase in the incidence of severe streptococcal infections (Davies et al., “Invasive group A streptococcal infections in Ontario, Canada. Ontario group A Streptoccal study group,”
N. Engl. J. Med.
335:547-554, 1966) and in the incidence of rheumatic fever (Veasey et al., “Resurgence of acute rhematic fever in the intermountain region of the United States,”
N. Eng. J. Med.
316:421-427, 1989).
Although streptococcal infections can be generally treated with antibiotics, in at least 4% of cases the infection leads to acute rheumatic fever. This disease is particularly prevalent in developing countries such as India, where millions of school-age children are affected.
The present invention provides a new Group A streptococcal vaccines with enhanced immunogenicity, and further, provides other related advantages.
SUMMARY OF THE INVENTION
Briefly stated , the present invention provides immunogenic synthetic fusion polypeptides which stimulate an immune response against Group A streptococci. Within one aspect such polypeptides comprise (a) at least two immunogenic polypeptides from a Group A streptococci of at least 10 amino acids in length which are capable of stimulating an immune response against Group A streptococci, and a peptide C terminal to the immunogenic polypeptide which protects the immunogenicity of the immunogenic portion. Within preformed embodiments, the C-terminal peptide is not required to stimulate an immune response against Group A streptococci and hence, may be an inconsequential non-immunogenic peptide, or a reiterated immunogenic polypeptide. Within certain embodiments, the immunogenic polypeptide can be obtained from a wide variety of Group A streptococci (ranging from “1” to greater than “90”), including for example, Types 1, 1.1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 18, 19, 22, 24, 28, 30, 48, 49, 52, 55 and 56.
Within other aspects of the present invention, vaccinating agents are provided for promoting an immune response against Group A streptococci, comprising (a) at least two immunogenic polypeptides from a Group A streptococci of at least 10 amino acids in length which are capable of stimulating a protective immune response against Group A streptococci, and (b) a peptide C terminal to the immunogenic polypeptide which protects the immunogenicity of the immunogenic portion, wherein the C-terminal peptide is not required to stimulate an immune response against Group A streptococci. As above, the polypeptide may be selected from a wide variety of Group A streptococci (ranging from “1” to greater than “90”), including for example, types 1.1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 18, 19, 22, 24, 28, 30, 48, 49, 52, 55 and 56. Within certain further embodiments, the vaccinating agent may further comprise an adjuvant, such as, for example, alum, Freund's adjuvant, and/or an immunomodulatory cofactor e.g., (IL-4, IL-10, &ggr;-IFN, or IL-2, IL-12 or IL-15).
Also provided are methods for vaccinating a host against Group A streptococci infections, comprising administering a vaccinating agent as described above.
REFERENCES:
patent: 4284537 (1981-08-01), Beachey
patent: 4454121 (1984-06-01), Beachey
patent: 4521334 (1985-06-01), Beachey
patent: 4597967 (1986-07-01), Beachey
patent: 4705684 (1987-11-01), Beachey
patent: 4784984 (1988-11-01), Yamanaka et al.
patent: 4919930 (1990-04-01), Beachey et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5985654 (1999-11-01), Fischetti et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6419932 (2002-07-01), Dale
patent: WO 94/06421 (1994-03-01), None
Dale J Exp Med 163=1191-1202, 1986.*
Beachey J Immunol 136(6)=2287-2292, 1986.*
Dale Vaccine 14(10) 944-8, Jul. 1996.*
Wittner Infection and Immunity 15(1)=104-108, 1977.*
Dale J Immunol. 151(4)=2188-2194, 1993.*
Beall J Clin Microbiol 34(4)=953-958, Apr. 1996.*
Mori et al. Pediatric Res. 39: 336-342, Feb. 1996.*
Fischetti et al. Science 244: 1487-1490, 1989.*
Hruby et al. PNAS 88: 3190-3194, 1991.*
Marston et al. In: Methods in Enzymology, Guide to Protein Purification. (Ed) MP Deutscher. vol. 182, section 20, pp. 264-276, 1991.*
Vashistha et al. J. Immunol. 150: 4693-4701, May 1993.*
Dale et al. J. Infect. Dis. 171: 1038-1041, 1995 (abstract).*
Ada,Fundamental Immunology, William E. Paul, M.D. (ed.), 2ndEdition, Raven Press, New York, 1989, pp. 1010-1011.
Baird et al., “Epitopes Of Group A Streptococcal M Protein Shared With Antigens Of Articular Cartilage And Synovim,”The Journal Of Immunology 146(9):3132-3137, 1991.
Beachey and Ofek, “Epithelial Cell Binding Of Group A Streptococci By Lipoteichoic Acid On Fimbriae Denuded Of M Protein,”The Journal Of Experimental Medicine 143:759-771, 1976.
Beachey and Seyer, “Protective And Nonprotective Epitopes Of Chemically Synthesized Peptides Of The NH2-Terminal Region Of Type 6 Streptococcal M Protein,”The Journal Of Immunology 136(6):2287-2292, 1986.
Beachey and Seyer,Seminars in Infectious Disease. Volume IV Bacterial Vaccines, Thieme-Stratton Inc., New York, New York, 1982, Chapter Fifty-Seven, “Primary Structure And Immuno-Chemistry Of Group A Streptococcal M Proteins,” pp. 401-410.
Beachey and Stollerman, “Mediation of Cytotoxic Effects of Streptococcal M Protein by Nontype-Specific Antibody in Human Sera,”The Journal of Clinical Investigation 52.2563-2570, 1973.
Beachey and Stollerman, “Toxic Effects Of Steptococcal M Protein On Platelets And Polymorphonuclear Leukocytes In Human Blood,”The Journal Of Experimental Medicine 134: 351-365, 1971.
Beachey et al., “Human Immune Response To Immunization With a Structurally Defined Polypeptide Fragment Of Streptococcal M Protein,”J. Exp. Med. 150:862-877, 1979.
Beachey et al., “Immunogenicity In Animals And Man Of A Structurally Defined Polypeptide Of Streptococcal M Protein,”Transactions Of The Association Of American Physicians,vol. XCII:pp. 346-354, 1979.
Beachey et al., “Opsonic Antibodies Evoked By Hybrid Peptide Copies Of Types 5 and 24 Streptococcal M Proteins Synthesized In Tandem,”J. Exp. Med. 163: 1451-1458, 1986.
Beachey et al., “Peptic Digestion of Streptococcal M Protein. II. Extraction of M Antigen from Group A Streptococci With Pepsin,”Infection And Immunity 9(5):891-896, 1974.
Beachey et al., “Primary Structure of Protective Antigens of Type 24 Streptococcal M Protein,”The Journal Of Biological Chemistry 255(13):6284-6289, 1980.
Beachey et al., “Protective Immunogenicity And T Lymphocyte Specificity Of A Trivalent Hybrid Peptide Containing NH2-Terminal Sequences Of Types 5, 6, And 24 M Proteins Synthesized In Tandem,”The Journal Of Experimental Medicine 166:647-656, 1987.
Beachey et al., “Purification And Properties Of M Protein Extracted From Group A Streptococci With Pepsin: Covalent Structure Of The Amino Terminal Region Of Type 24 M Antigen,”The Journal Of Experimental Medicine 145:1469-1483, 1977.
Beachey et al., “Repeating Covalent Structure and Protective Immunogenicity of Native and Synthetic Polypeptide Fragments of Type 24 Streptococcal M Protein,”The Journal Of Biological Chemistry 258(21):13250-13257, 1983.
Beachey et al., “Repeating covalent structure of streptococcal M protein,”Proc. Natl. Acad. Sci. USA 75(7):3163-31
Devi S.
Seed Intellectual Property Law Group PLLC
University of Tennessee Research Foundation
LandOfFree
Group a streptococcal vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group a streptococcal vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group a streptococcal vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3237889